Zealand Pharma Initiates Phase 2 ZYNERGY Trial of Petrelintide and Enicepatide Combination for Obesity

19 November 2026 | Thursday | News

The Phase 2 dose-finding trial will evaluate once-weekly co-administration of petrelintide, an investigational amylin analogue, and enicepatide, a GLP-1/GIP receptor agonist, in adults with obesity or overweight and at least one weight-related condition. The study will assess weight loss, safety and tolerability compared with placebo and each treatment alone
Image Source: Public Domain

Image Source: Public Domain

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, announces initiation of ZYNERGY, a Phase 2 dose-finding trial in participants with obesity or overweight with at least one weight-related comorbidity. The trial compares once-weekly co-administration of petrelintide (an investigational human amylin analog), and enicepatide (an investigational GLP-1/GIP receptor agonist), versus placebo, petrelintide monotherapy, and enicepatide monotherapy with regards to effect on body weight, safety, and tolerability1.

“The initiation of the Phase 2 trial with petrelintide co-administered with enicepatide marks an important milestone in our ambition to build a leading amylin-based franchise for chronic weight management," said David Kendall, MD, Chief Medical Officer at Zealand Pharma. "As demonstrated in separate Phase 2 trials, petrelintide’s tolerability profile, which is largely comparable to placebo, paired with the promising efficacy of enicepatide, makes this combination study a compelling and natural next step. This study is designed to explore the effect of two complementary mechanisms, aiming to deliver both substantial weight loss and an improvement in cardiometabolic risk markers while maintaining a competitive tolerability profile."

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close